TRDA Entrada Therapeutics, Inc.
Price Chart
Executive Summary
Entrada Therapeutics reported Q1 2026 results with a net loss of $39.7M ($0.95/share), beating consensus EPS of -$1.06 by 10.4%. Collaboration revenue plunged to $0.9M from $20.6M a year ago as the Vertex research plan completed, but the company highlighted positive clinical data from ENTR-601-44 in Duchenne muscular dystrophy, showing favorable safety and early functional benefit.
Actionable Insight
The positive ENTR-601-44 data is a major catalyst but the sharp revenue decline and widening loss cap upside. Watch for upcoming ELEVATE-45-201 data in mid-2026 and further cohort readouts by year-end to validate the platform.
Key Facts
- Net loss widened to $39.7M in Q1 2026 from $17.3M in Q1 2025 due to higher R&D costs and lower collaboration revenue.
- Collaboration revenue declined to $0.9M from $20.6M YoY as the Vertex VX-670 research plan substantially completed.
- Positive topline results from ELEVATE-44-201 Cohort 1: favorable safety, statistically significant improvement in Time to Rise velocity.
- Cash, cash equivalents and marketable securities of $254.9M, expected to fund operations into Q3 2027.
- EPS of -$0.95 beat the -$1.06 consensus by 10.4%.
Financial Impact
Net loss increased 129% YoY to $39.7M; revenue decreased 96% to $0.9M.
Risk Factors
- Clinical development risk for DMD programs; reliance on positive data from ongoing and future cohorts.
- Dependence on Vertex partnership for VX-670; any setbacks could impact investor sentiment.
- Cash burn rate; runway only into Q3 2027 without additional financing or partnership milestones.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289842 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 10, 2026
2d ago
|
8-K
| $5.96 awaiting T+1 | awaiting T+1 | — | $6.46 (+8.39%) |
|
Jun 2, 2026
11d ago
|
Press Release
| $6.64 $6.58 | ▼ −0.90% | ▼ −0.18% | $6.46 (−2.71%) |
|
May 7, 2026
5w ago
|
Press Release
| $6.85 $6.84 | ▼ −0.15% | ▼ −0.98% | $6.46 (−5.69%) |
|
May 4, 2026
5w ago
|
144
| $15.75 $16.03 | ▲ +1.78% | ▲ +0.39% | $6.46 (−58.98%) |
|
May 4, 2026
5w ago
|
Insider Cluster
| $15.79 $15.75 | ▲ +0.25% | ▲ +1.05% | $6.46 (+59.09%) |
|
Apr 24, 2026
7w ago
|
DEFA14A
| $12.63 $12.96 | ▲ +2.61% | ▲ +2.45% | $6.46 (−48.85%) |
|
Mar 4, 2026
14w ago
|
Insider Cluster
| $12.50 $11.62 | ▼ −7.04% | ▼ −6.47% | $6.46 (−48.32%) |
|
Feb 26, 2026
15w ago
|
8-K
| $12.79 $11.93 | ▲ +6.72% | ▲ +6.27% | $6.46 (+49.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access